Biotech & Life Sciences
-
PureHealth Research Debuts “Natural GLP-1 Support” for Needle-Free Weight Care
PureHealth Research has officially entered the metabolic health race with its Natural GLP-1 Support collection. Headlined by the 9-ingredient formula GLP ON, the line aims to provide a needle-free, non-prescription alternative to the high-cost injectable GLP-1 agonists that have dominated the market recently. I’m noticing a strategic shift here. While many “nature’s Ozempic” products rely
-
New Hope for PKU: Adolescents 12+ Gain Access to Breakthrough Enzyme Therapy
In a significant expansion of treatment options for the metabolic disease community, the U.S. Food and Drug Administration (FDA) has approved PALYNZIQ® (pegvaliase-pqpz) for pediatric patients 12 years of age and older with Phenylketonuria (PKU). This supplemental approval, announced on February 27, 2026, marks PALYNZIQ as the only enzyme substitution therapy available for this younger
-
FDA Clearance: Cara Medical Unveils Noninvasive 3D Mapping for Cardiac Conduction
In a landmark decision for cardiac care, the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Cara Medical Ltd. for its CARA System. This platform is the first of its kind to provide noninvasive, patient-specific 3D visualization of the cardiac conduction system—the internal “electrical wiring” of the heart—using standard CT angiography (CTA)
-
Clinical Milestone: Argo Biopharma Reports 100% Attack Reduction in HAE Phase II Trial
In a significant update for the Hereditary Angioedema (HAE) community, Argo Biopharmaceutical has announced positive Phase II interim results for BW-20805, its investigational siRNA therapeutic. The data, presented as a late-breaking abstract at the 2026 AAAAI Annual Meeting, highlights the drug’s potential as a “best-in-class” long-acting prophylactic. I’m seeing a clear shift in the HAE
-
Biopharma Partnership: Astellas and Vir Bio Collaborate on Precision Oncology
Astellas Pharma and Vir Biotechnology just announced a global strategic collaboration. The deal centers on VIR-5500, an investigational T-cell engager (TCE) for prostate cancer. I’m looking at the financial terms—it’s a massive commitment. Vir is receiving $335 million upfront with a total deal value potentially hitting $1.7 billion. I see a clear signal here: the
-
Johnson & Johnson Reports Long‑Term TREMFYA Data: 80% in Remission
Johnson & Johnson (NYSE:JNJ) has announced new long‑term data from the QUASAR LTE study, showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis. More than 80% of patients were in clinical remission, over 50% achieved endoscopic remission, and nearly 79% showed histo‑endoscopic
-
Vanda Wins FDA Nod for BYSANTI, a New Antipsychotic Tablet
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has announced FDA approval of BYSANTI™ (milsaperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. BYSANTI™ is a new chemical entity in the atypical antipsychotic class, offering patients and providers a novel therapeutic option with a
-
Brookdale Raises Liquidity to $377.7M After Refinancing $550M of Debt
Brookdale Senior Living Inc. (NYSE:BKD) announced results for the quarter and the year ending 2025, consistent with preliminary figures shared in January. The company highlighted stronger occupancy, improved revenue per available unit, and progress on refinancing and portfolio optimization. Fourth quarter highlights Same community results showed resident fees up 5.0 percent, with occupancy climbing 250
-
Retevmo Delivers Clinically Meaningful Event‑Free Survival in Phase 3 Trial
Eli Lilly and Company (NYSE:LLY) announced positive topline results from its Phase 3 LIBRETTO‑432 trial, evaluating Retevmo (selpercatinib) as adjuvant therapy in patients with early‑stage RET fusion‑positive non‑small cell lung cancer (NSCLC). The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in event‑free survival compared to placebo. Trial highlights Overall
-
Hands‑Free AI Reading Now Live in U.S. Radiology Practices
Coreline Soft has partnered with INFINITT North America to embed its AVIEW AI platform directly into the INFINITT PACS environment. The result is a fully automated, zero‑click AI reading solution now live in U.S. radiology practices. Radiologists can access AI‑powered insights without extra logins or workflow interruptions, making advanced technology part of everyday clinical practice.
